首页> 外文学位 >LDL receptor-related protein 6 (LRP6) in Wnt signaling and breast cancer tumorigenesis.
【24h】

LDL receptor-related protein 6 (LRP6) in Wnt signaling and breast cancer tumorigenesis.

机译:Wnt信号和乳腺癌肿瘤发生中的LDL受体相关蛋白6(LRP6)。

获取原文
获取原文并翻译 | 示例

摘要

Breast cancer is a diverse malignancy; understanding the molecular mechanisms driving tumor progression will facilitate development of targeted therapies. For example, tamoxifen, an anti-estrogen agent, used for treating estrogen receptor (ER)-positive breast tumors, and trastuzumab, a monoclonal antibody targeting HER2-overexpressing tumors, have benefitted specific subsets of breast cancer patients. However, the enormous variation in breast cancer initiation and growth complicate biological approaches to this malignancy and challenge the effectiveness of current therapies. Elucidation of novel, targetable signaling pathways in breast cancers would provide means of addressing current deficiencies in the treatment of the disease.;The Wnt signaling pathway is involved in various differentiation events during embryonic development and can lead to tumor formation when aberrantly activated. Aberrant Wnt activation is found in 40-60% of breast cancers. However, because mutations in the classical intracellular components of the Wnt signaling pathway are rare, the underlying cause of this aberrant activation remains elusive and may involve dysregulation of upstream elements. In this thesis, we found that overexpression of LRP6, a Wnt signaling co-receptor, plays a crucial role in the pathogenesis of a subtype of human breast tumor. LRP6 was increased more frequently in ER or HER2-negative or triple-negative breast tumors that are either harder to treat or more likely to recur. We further demonstrated that suppression of LRP6 expression and function significantly inhibits Wnt signaling and breast tumor growth in vitro and in vivo.;Mesd (mesoderm development) was previously identified as a specialized chaperone of LRP5/6. Using NMR structural and molecular tools, we first showed that the core chaperone domain of Mesd is required for the proper folding of LRP5/6, while its C-terminal escort domain ensures a safe trafficking of LRP5/6 from the ER to Golgi by preventing premature ligand binding. With the goal of developing a novel strategy of inhibiting Wnt signaling at the cell surface, we further demonstrated that Mesd could serve as an LRP5/6 inhibitor to reduce tumor burden in Wnt-driven breast cancer without causing undesirable side effects. Together, our studies highlight LRP6 as a potential therapeutic target in breast cancer, and introduce Mesd as a promising antitumor agent for treating breast cancer subtypes with Wnt activation at the cell surface.;Trafficking of receptors to the cell surface, ligand/antagonists modulations, and endocytosis of cell surface receptors are important regulatory events of signal transduction pathways. LRP6 consists of four beta-propeller domains flanked by EGF repeats (BP) at its extracellular region. In this thesis, we extensively analyzed the folding and ligand-binding properties of LRP6 BP. The cooperative folding and maturation were observed between BP1 & BP2 and BP3 & BP4. BP12 and BP34 serve as functional units displaying different ligand binding preferences. Another aim of this thesis is to identify the endocytosis motifs of LRP6 at its cytoplasmic tail and investigate the relationship between LRP6 endocytic trafficking and Wnt signaling activation. Using flow cytometry, immunofluorecent staining, and endocytosis assay, we showed that LRP6 mutant with defective tyrosine-based signals (Y mutant) in its cytoplasmic tail displayed increased cell surface distribution. We further found that Wnt3a ligands and mutation of tyrosine-based signals in LRP6 tail redistribute this receptor to lipid rafts, which are membrane microdomains that consist of a dynamic assembly of cholesterol and glycosphingolipids. LRP6 Y mutant also exhibited higher signaling in response to Wnt3a ligand stimulation compared to wild-type, and this activation was blocked when cells were treated with Nystatin, a lipid raft-disrupting agent that inhibits caveolae-mediated endocytosis. Our results suggest that tyrosine-based signals serve as an endocytosis motif in LRP6 tail and play an important role in the determination of LRP6 internalization route and Wnt signaling activation.;Taken together, our studies provide a comprehensive appreciation for the dynamic regulation and pathological roles of LRP6 in Wnt signaling and tumorigenesis.
机译:乳腺癌是一种多样的恶性肿瘤。了解驱动肿瘤进展的分子机制将有助于靶向治疗的发展。例如,用于治疗雌激素受体(ER)阳性乳腺肿瘤的抗雌激素药物他莫昔芬和靶向过表达HER2的肿瘤的单克隆抗体曲妥珠单抗已经使乳腺癌患者的特定亚型受益。然而,乳腺癌起始和生长的巨大差异使针对这种恶性肿瘤的生物学方法变得复杂,并挑战了当前疗法的有效性。阐明乳腺癌中新颖的,可靶向的信号传导途径将为解决目前在该疾病治疗中的不足提供手段。Wnt信号传导途径参与胚胎发育期间的各种分化事件,并且在异常激活时可导致肿瘤形成。在40-60%的乳腺癌中发现异常Wnt激活。但是,由于Wnt信号传导途径的经典细胞内成分很少发生突变,因此这种异常激活的根本原因仍然难以捉摸,并且可能涉及上游元件的失调。在本论文中,我们发现Wnt信号共受体LRP6的过表达在人类乳腺肿瘤亚型的发病机理中起着至关重要的作用。 ER或HER2阴性或三阴性的乳腺肿瘤中LRP6的升高更为频繁,这种肿瘤难以治疗或复发的可能性更高。我们进一步证明,抑制LRP6表达和功能在体内外显着抑制Wnt信号传导和乳腺肿瘤的生长。Mesd(中胚层发育)以前被鉴定为LRP5 / 6的专门伴侣。我们首先使用NMR结构和分子工具研究了Mesd的核心分子伴侣结构域是LRP5 / 6正确折叠所必需的,而其C端伴游结构域则通过防止以下行为确保了LRP5 / 6从ER到高尔基体的安全运输过早的配体结合。以开发抑制细胞表面Wnt信号传导的新策略为目标,我们进一步证明了Mesd可以作为LRP5 / 6抑制剂来减轻Wnt驱动的乳腺癌中的肿瘤负担,而不会引起不良副作用。总之,我们的研究突出了LRP6在乳腺癌中的潜在治疗靶点,并介绍了Mesd作为一种有前途的抗肿瘤药物,用于治疗在细胞表面具有Wnt活化作用的乳腺癌亚型;受体向细胞表面的转运,配体/拮抗剂的调节,细胞表面受体的内吞和胞吞作用是信号转导途径的重要调节事件。 LRP6由四个β螺旋结构域组成,在其细胞外区域旁有EGF重复序列(BP)。在本文中,我们广泛分析了LRP6 BP的折叠和配体结合特性。在BP1和BP2与BP3和BP4之间观察到协同折叠和成熟。 BP12和BP34用作显示不同配体结合偏好的功能单元。本论文的另一个目的是鉴定LRP6在其细胞质尾部的内吞作用基序,并研究LRP6内吞运输与Wnt信号激活之间的关系。使用流式细胞仪,免疫荧光染色和内吞作用测定,我们显示LRP6突变体在其细胞质尾部具有基于酪氨酸的信号缺陷(Y突变体)显示出增加的细胞表面分布。我们进一步发现,Wnt3a配体和LRP6尾巴中基于酪氨酸的信号突变将该受体重新分布到脂质筏上,该筏是由胆固醇和鞘糖脂的动态组装组成的膜微区。与野生型相比,LRP6 Y突变体还表现出对Wnt3a配体刺激的更高信号传导,并且当用Nystatin(一种抑制筏介导的内吞作用的脂质筏破坏剂)处理细胞时,该激活被阻断。我们的研究结果表明基于酪氨酸的信号充当LRP6尾部的内吞作用基序,并在确定LRP6内在化途径和Wnt信号激活中起重要作用。综上,我们的研究为动态调节和病理作用提供了全面的认识在Wnt信号传导和肿瘤发生中的作用。

著录项

  • 作者

    Liu, Chia-Chen.;

  • 作者单位

    Washington University in St. Louis.;

  • 授予单位 Washington University in St. Louis.;
  • 学科 Biology Molecular.;Biology Cell.
  • 学位 Ph.D.
  • 年度 2010
  • 页码 247 p.
  • 总页数 247
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号